Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)

Volume 23, 46 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Design

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 73rd of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

William A. Banks
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.052
5 - Year: 3.132

Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain

Current Pharmaceutical Design, 20(38): 6042-6047.

Author(s): Alessandra Del Bufalo, Alfredo Cesario, Gianluca Salinaro, Massimo Fini and Patrizia Russo.

Affiliation: Laboratory of Systems Approaches and Non Communicable Diseases, IRCCS "San Raffaele Pisana", Via di Valcannuta, 247, I-00166 Roma, Italia.


Chronic pain is a widespread healthcare problem affecting not only the patient but in many ways all the society. Chronic pain is a disease itself that endures for a long period of time and it is resistant to the majority of medical treatments that provide modest improvements in pain and minimum improvements in physical and emotional functioning. More co-existing chronic pain conditions may be present in the same individual (patient). The α 9α 10 nicotinic acetylcholine receptor (nAChR) may be a potential target in the pathophysiology of chronic pain, as well in the development of breast and lung cancers. α-conotoxins (α-CNT) are small peptides used offensively by carnivorous marine snails known as Conus that target nAChR. Among α-CNT there are potent and selective antagonists of α 9α 10 nAChR such as RgIA and Vc1.1 that produces both acute and long lasting analgesia. Moreover, these peptides accelerate the recovery of nerve function after injury, likely through immune/inflammatory-mediated mechanisms. We review the background, findings, implications and problems in using compounds that act on α 9α 10 nAChR.


Chronic pain, α 9α 10 nAChR, α -conotoxins, pathophysiology, RgIA, Vc11.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 20
Issue Number: 38
First Page: 6042
Last Page: 6047
Page Count: 6
DOI: 10.2174/1381612820666140314150634
Price: $58
4th Microbiome R&D and Business Collaboration Forum: EuropeRNA Therapeutics 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science